<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982329</url>
  </required_header>
  <id_info>
    <org_study_id>12/15S</org_study_id>
    <nct_id>NCT03982329</nct_id>
  </id_info>
  <brief_title>Impact of nrTMS Therapy on the Progress of Neurorehabilitation</brief_title>
  <official_title>Evaluation of the Benefit of Navigated Repetitive Transcranial Magnetic Stimulation for Therapy of Surgery-related Motor Deficits in Brain Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-frequency navigated repetitive transcranial magnetic stimulation (nrTMS) of the
      non-damaged hemisphere to increase cortical excitability of the damaged hemisphere and to
      reduce the increased neuronal inhibition in patients suffering from new surgery-related
      paresis after brain tumor resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative loss of motor function greatly impairs the patients' quality of life and life
      expectancy of patients with brain tumors is significant limited. Hence the reduction of time
      spent on neurorehabilitation is very important.

      Inclusion of patients that underwent brain tumor resection with a surgery-related paresis of
      the upper extremity.

      Randomized controlled and double blinded trial - 2/3 nrTMS, 1/3 sham. Fifteen minutes
      low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days: nrTMS group or
      sham group. Thirty minutes physical therapy of the upper extremity in both groups.

      MRI, nTMS motor mapping, assessments for motor status of upper extremity including
      Fugl-Meyer-Assessment (FMA), National Institution of Health Stroke Scale (NIHSS), Jebsen
      Taylor Hand Function Test (JTHFT), Nine Hole Peg Test (NHPT), and Karnofsky Performance Scale
      (KPS) postoperatively, after the 7th day of intervention and after 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2/3 nrTMS, 1/3 sham</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Fugl-Meyer Assessment (FMA)</measure>
    <time_frame>Between first day of intervention and 3-months follow up</time_frame>
    <description>Assessment upper extremity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nine Hole Peg Test (NHPT)</measure>
    <time_frame>First day of intervention = postoperatively, after the 7th day of intervention and after 3 months</time_frame>
    <description>Fine motor skills upper extremity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>First day of intervention = postoperatively, after the 7th day of intervention and after 3 months</time_frame>
    <description>The scale measures neurological outcome; Total score is reported; Scores on the NIHSS range from 0 to 42, with higher scores indicating more severe disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Jebsen Taylor Hand Function Test (JTHFT)</measure>
    <time_frame>First day of intervention = postoperatively, after the 7th day of intervention and after 3 months</time_frame>
    <description>Functionality upper extremity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status (KPS)</measure>
    <time_frame>First day of intervention = postoperatively, after the 7th day of intervention and after 3 months</time_frame>
    <description>The scale measures general oncological outcome; the total score is reported; Scores on the KPS scale range from 0% to 100%, with higher scores indicating less disability and and better quality of life in cancer patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Transcranial Magnetic Stimulation, Repetitive</condition>
  <arm_group>
    <arm_group_label>nrTMS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated repetitive transcranial magnetic stimulation</intervention_name>
    <arm_group_label>nrTMS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>physical therapy</intervention_name>
    <arm_group_label>nrTMS group</arm_group_label>
    <arm_group_label>sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New surgery-related paresis of upper extremity after brain tumor resection

          -  Written informed consent for participation

        Exclusion Criteria:

          -  Contraindications for MRI

          -  Contraindications for nrTMS

          -  Only biopsy instead of tumor resection

          -  Patients without preserved MEP response as measured by postoperative nTMS motor
             mapping
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro M. Krieg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, School of Medicine, TU Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandro M. Krieg, MD</last_name>
    <phone>+498941402151</phone>
    <email>sandro.krieg@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Ille, MD</last_name>
    <phone>+498941402151</phone>
    <email>sebastian.ille@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro M Krieg, MD, MBA</last_name>
      <email>sandro.krieg@tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Sandro M. Krieg</investigator_full_name>
    <investigator_title>Attending Neurosurgeon</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

